Cited by 330Nanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsImmunotherapy and Immune Responses

Breaking Down the Barriers to Precision Cancer Nanomedicine

von Roemeling, Christina, Jiang, Wen, Chan, Charles K., Weissman, Irving L., Kim, Betty Y.S.·2017·Trends in Biotechnology

Abstract

Nanomedicine offers unique advantages in treating human cancers. However, physiological and pathological barriers within normal and disease tissues, which are highly variable among individuals, often hinder its effectiveness. The body possesses specific innate responses to nanoparticles (NPs), which when combined with unique pathophysiological signatures in the tumor microenvironment, can severely limit the utility of nanomedicine in the oncological setting. Furthermore, with the successes of cancer immunotherapies, understanding nanoimmune interactions and developing immune-smart cancer nanomedicine that can take advantage of the body's immune functions will increasingly become clinically relevant. Therefore, a better understanding of the important native and acquired biological processes that dictate the fate of nanomedicine is integral to developing more effective individualized platforms for treating cancer patients.

Integrity signals

Registry

Crossref · 10.1016/j.tibtech.2016.07.006

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
von Roemeling, C., Jiang, W., Chan, C. K., Weissman, I. L., & Kim, B. Y. S.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Stanford Medicine (US)
  • Mayo Clinic (US)
Corresponding author
  • Jiang, Wen
  • Kim, Betty Y.S.
Venue
Trends in Biotechnology
Publisher
Elsevier BV
Published
2017-02
Volume
35
Issue
2
Pages
159-171
ISSN
0167-7799 (ISSN-L)
OpenAlex
W2481327576
Cited by
330
References
98
Citations by year
2026: 9 · 2025: 18 · 2024: 35 · 2023: 36 · 2022: 44 · 2021: 44 · 2020: 47 · 2019: 47 · 2018: 27 · 2017: 22
FWCI
1.71
Type
journal article
Language
en
Open access
closed
Locations
  • Trends in biotechnology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
cancer nanomedicine, precision oncology, tumor microenvironment, cancer immunotherapy
MeSH terms
Animals, Humans, Immunity, Innate, Immunotherapy, Neoplasms, Nanoparticles, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review